Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

PHASE3CompletedINTERVENTIONAL
Enrollment

365

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
AnemiaLeukemiaLymphomaLymphoproliferative DisorderMultiple Myeloma and Plasma Cell NeoplasmPrecancerous ConditionUnspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

epoetin alfa

Trial Locations (18)

32224

Mayo Clinic, Jacksonville

48106

CCOP - Michigan Cancer Research Consortium, Ann Arbor

55805

CCOP - Duluth, Duluth

55905

Mayo Clinic Cancer Center, Rochester

57104

CCOP - Sioux Community Cancer Consortium, Sioux Falls

57709

Rapid City Regional Hospital, Rapid City

58122

CCOP - Merit Care Hospital, Fargo

58201

Altru Cancer Center, Grand Forks

61602

CCOP - Illinois Oncology Research Association, Peoria

61801

CCOP - Carle Cancer Center, Urbana

68106

CCOP - Missouri Valley Cancer Consortium, Omaha

74136

CCOP - Oklahoma, Tulsa

85259-5404

CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale

50309-1016

CCOP - Iowa Oncology Research Association, Des Moines

51101-1733

Siouxland Hematology-Oncology, Sioux City

67214-3882

CCOP - Wichita, Wichita

43623-3456

CCOP - Toledo Community Hospital, Toledo

17822-2001

CCOP - Geisinger Clinic and Medical Center, Danville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00058331 - Epoetin Alfa in Treating Anemia in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter